Erschienen in:
01.03.2016 | Original Article
Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML
verfasst von:
Jae-Sook Ahn, Hyeoung-Joon Kim, Yeo-Kyeoung Kim, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Nan Young Kim, Seung Hyun Choi, Chul Won Jung, Jun-Ho Jang, Hee Je Kim, Joon Ho Moon, Sang Kyun Sohn, Jong-Ho Won, Sung-Hyun Kim, Dennis Dong Hwan Kim
Erschienen in:
Annals of Hematology
|
Ausgabe 4/2016
Einloggen, um Zugang zu erhalten
Abstract
The prognostic significance of molecular mutations (FLT3-ITD, NPM1, and CEBPA mutations) was examined in patients with normal-karyotype acute myeloid leukaemia (NK-AML) after allogeneic haematopoietic cell transplantation (HCT). In total, 115 patients received allogeneic HCT for NK-AML and were evaluated for FLT3-ITD, NPM1, and CEBPA mutations in diagnostic samples and for long-term outcomes following HCT, retrospectively. The prevalences of FLT3-ITDpos, NPM1
mut, and CEBPA
dm (double mutations) were 32.2, 43.5, and 24.6 %, respectively. The triple-negative group (NPM1
wild/FLT3-ITDneg/non-CEBPA
dm) showed a similar transplant outcome to those in the favourable European LeukemiaNet (ELN) risk group for overall survival (OS) (60.9 vs. 63.7 %; p = 0.810), but a more favourable OS than others in the intermediate-I risk group (40.0 %; p = 0.034). Also, the triple-negative group showed a similar relapse rate at 5 years compared with those in the favourable risk group (9.7 vs. 15.5 %; p = 0.499), but a lower rate of relapse than the others in the intermediate-I risk group (15.5 vs. 48.6 %; p = 0.004). The 5-year relapse incidences were 4.0 % (NPM1
mut/FLT3-ITDneg), 14.7 % (CEBPA
dm), 15.5 % (NPM1
wild/FLT3-ITDneg/non-CEBPA
dm), 39.1 % (NPM1
mut/FLT3-ITDpos/non-CEBPA
dm), and 66.7 % (NPM1
wild/FLT3-ITDpos/non-CEBPA
dm). Thus, the triple-negative (NPM1
wild/FLT3-ITDneg/non-CEBPA
dm) group showed favourable long-term outcomes after allogeneic HCT in NK-AML, similar to those of the favourable risk group by the ELN risk classification.